← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Thermo Fisher Scientific TMO $249B	1,322	+16	+1%	$73B
2	2 Danaher DHR $158B	1,247	+40	+3%	$54.1B
3	3 Novartis NVS $279B	987	-26	-3%	$19.3B
4	4 Illumina ILMN $41B	747	+55	+8%	$37.3B
5	5 Agilent Technologies A $49.1B	669	-23	-3%	$16.9B
6	6 Regeneron Pharmaceuticals REGN $80.1B	624	+4	+0.6%	$25.1B
7	7 Revvity RVTY $17B	375	0	0%	$7.8B
8	8 Charles River Laboratories CRL $14.4B	348	+15	+5%	$5.19B
9	9 Sarepta Therapeutics SRPT $1.78B	318	+49	+18%	$7.92B
10	10 Alnylam Pharmaceuticals ALNY $30B	310	+17	+6%	$9.02B
11	11 Ionis Pharmaceuticals IONS $7.1B	308	-18	-6%	$4.93B
12	12 DELISTED bluebird bio BLUE	307	+4	+1%	$8.41B
13	13 DELISTED CATALENT, INC. CTLT	262	-12	-4%	$5.63B
14	14 Myriad Genetics MYGN $397M	258	-2	-0.8%	$2.75B
15	15 Qiagen QGEN $9.41B	232	+1	+0.4%	$5.42B
16	16 Azenta AZTA $1.63B	229	+9	+4%	$2.22B
17	17 Bruker BRKR $8.47B	227	0	0%	$3.03B
18	18 Editas Medicine EDIT $349M	214	+17	+9%	$1.15B
19	19 DELISTED SANGAMO THERAPEUTICS INC SGMO	210	+2	+1%	$919M
20	20 Regenxbio RGNX $454M	177	+57	+48%	$1.87B
21	21 CRISPR Therapeutics CRSP $4.86B	174	+39	+29%	$1.09B
22	22 Precigen PGEN $2.64B	166	0	0%	$1.53B
23	23 PTC Therapeutics PTCT $4.98B	166	+18	+12%	$1.45B
24	24 Ultragenyx Pharmaceutical RARE $1.47B	158	-7	-4%	$3.75B
25	25 Intellia Therapeutics NTLA $1.6B	156	+26	+20%	$789M